ReviewInternational journal of hematology2012
Mutations in epigenetic regulators in myelodysplastic syndromes.
Review in International journal of hematology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 30 citations in OpenAlex.
- [Tatton-Brown-Rahman syndrome associated with the DNMT3A gene: a case report and literature review].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2020Review
- The roles of DNA, RNA and histone methylation in ageing and cancer.Nature reviews. Molecular cell biology · 2019Review
- Article
- The Tatton-Brown-Rahman Syndrome: A clinical study of 55 individuals withWellcome open research · 2018Article
- DNA Methylation and Adult Neurogenesis.Brain plasticity (Amsterdam, Netherlands) · 2017Review
- Digging deep into "dirty" drugs - modulation of the methylation machinery.Drug metabolism reviews · 2015Review
- Pulmonary Complications of Azanucleoside Therapy in Patients with Myelodysplastic Syndrome and Acute Myelogenous Leukemia.Case reports in hematology · 2015Article
- Mutations in the DNA methyltransferase gene DNMT3A cause an overgrowth syndrome with intellectual disability.Nature genetics · 2014Article
- Age-related epigenetic drift in the pathogenesis of MDS and AML.Genome research · 2014Article
- Functional characterization of a novel FGFR1OP-RET rearrangement in hematopoietic malignancies.Molecular oncology · 2014Article
- The molecular basis of myeloid malignancies.Proceedings of the Japan Academy. Series B, Physical and biological sciences · 2014Review
- Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations.The Journal of clinical investigation · 2013Article
- Detection of acquired hemoglobinopathy in children with hematological malignancies at disease onset: results form a national referral centre.International journal of hematology · 2013Article
- Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts.Haematologica · 2013Article
- [Myelodysplastic syndromes. Epidemiology, molecular and morphological characteristics and risk stratification].Der Pathologe · 2013Review
- Epigenetic aspects of MDS and its molecular targeted therapy.International journal of hematology · 2013Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Until recently, the genetic aberrations that are causally linked to the pathogenesis of myelodysplastic syndromes (MDS) and myeloproliferative neoplasms were largely unknown. Using novel technologies like high-resolution SNP-array analysis and next generation sequencing, various genes have now been identified that are recurrently mutated. Strikingly, several of the newly identified genes (ASXL1, DNMT3A, EZH2, IDH1 and IDH2, and TET2) are involved in the epigenetic regulation of gene expression. Aberrant epigenetic modifications have been described in many types of cancer, including myeloid malignancies. It has been proposed that repression of genes that are crucial for the cessation of the cell cycle and induction of differentiation might contribute to the malignant transformation of normal hematopoietic cells. Several therapies that aim to re-express silenced genes are currently being tested in MDS, like histone deacetylase inhibitors and hypomethylating agents. It will be interesting to assess whether patients carrying mutations in epigenetic regulators respond differently to these novel forms of epigenetic therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.